Anzemet Side Effects
Generic Name: dolasetron
Note: This document contains side effect information about dolasetron. Some of the dosage forms listed on this page may not apply to the brand name Anzemet.
Some side effects of Anzemet may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to dolasetron: oral tablet
Other dosage forms:
Along with its needed effects, dolasetron (the active ingredient contained in Anzemet) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking dolasetron:More common
- Chest pain or discomfort
- lightheadedness, dizziness, or fainting
- shortness of breath
- slow or irregular heartbeat
- unusual tiredness or weakness
- decrease in the amount of urine
- fast, pounding, or irregular heartbeat or pulse
- black, tarry stools
- bleeding gums
- bloating or swelling of the face, arms, hands, lower legs, or feet
- blood in the urine or stools
- blurred vision
- burning while urinating
- changes in skin color
- difficult or labored breathing
- difficult or painful urination
- difficulty with swallowing
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- frequent urination
- hives or welts
- increased volume of pale, dilute urine
- itching of the skin
- low blood pressure
- muscle twitching
- noisy breathing
- numbness and tingling of the face, fingers, or toes
- pain in the arms, legs, or lower back, especially pain in the calves or heels upon exertion
- pain, tenderness, or swelling of the foot or leg
- pale skin
- pale, bluish-colored, or cold hands or feet
- pinpoint red or purple spots on the skin
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- rapid weight gain
- red skin
- skin rash
- swelling of the face, ankles, or hands
- tightness in the chest
- tingling of the hands or feet
- troubled breathing with exertion
- unusual bleeding or bruising
- unusual weight gain or loss
- weak or absent pulses in the legs
Some side effects of dolasetron may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Acid or sour stomach
- stomach discomfort, upset, or pain
- Abnormal dreams
- bad, unusual, or unpleasant (after) taste
- bloody nose
- change in color vision
- change in taste
- changes in vision
- continuing ringing or buzzing or other unexplained noise in the ears
- darkened urine
- difficulty having a bowel movement (stool)
- difficulty seeing at night
- difficulty with moving
- feeling of constant movement of self or surroundings
- feeling of unreality
- feeling of warmth
- hearing loss
- increased sensitivity of the eyes to sunlight
- increased sweating
- joint pain
- loss of appetite
- muscle aching or cramping
- muscle pain or stiffness
- pain or burning sensation at the injection site
- pains in the stomach, side, or abdomen, possibly radiating to the back
- redness of the face, neck, arms, and occasionally, upper chest
- sensation of spinning
- sense of detachment from self or body
- shakiness and unsteady walk
- shakiness in the legs, arms, hands, or feet
- swollen joints
- trembling or shaking of the hands or feet
- unsteadiness, trembling, or other problems with muscle control or coordination
- weight loss
- yellow eyes or skin
For Healthcare Professionals
Applies to dolasetron: intravenous solution, oral tablet
In general, side effects have included fever (4.3%), fatigue (3.6%), pain (2.4%), and chills/shivering (2.0%).
In some controlled clinical trials, dolasetron (the active ingredient contained in Anzemet) was tested for use in the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy (CINV). Patients in these trials primarily received concurrent high-dose cisplatin. In other controlled trials, dolasetron was tested for use patients for the prevention or treatment of postoperative nausea and vomiting (PONV). For many of the effects listed below, whether the patient received concurrent chemotherapy was not specified in the literature.
Nervous system side effects including headaches (9.4% to 24.3%), lightheadedness (13%), and dizziness (2.2% to 5.5%) have been reported. Flushing, vertigo, paresthesia, and tremor have been reported infrequently. Ataxia and twitching have been reported rarely.
Gastrointestinal side effects have included appetite (12% to 26.6%), diarrhea (6.0% to 12.4%), nausea (6.3% to 7%), abdominal pain (3.2%), and constipation (3.2%). Dyspepsia, abdominal pain, and anorexia have been reported infrequently. Pancreatitis has also been reported rarely.
Increases in AST and ALT did not appear to be related to dose or duration of therapy, and were not associated with symptomatic hepatic disease.
Hepatic side effects have included abnormal hepatic function (3.6%) including transient increases in AST (SGOT) and/or ALT (SGPT) (less than 1%). Hyperbilirubinemia and increased GGT have been reported rarely.
Cardiovascular side effects have rarely included hypotension, edema, peripheral edema, Mobitz I AV block, chest pain, orthostatic hypotension, myocardial ischemia, syncope, severe bradycardia, palpitations, bradycardia, tachycardia, T wave change, ST-T wave change, sinus arrhythmia, extrasystole, poor R wave progression, bundle branch block, nodal arrhythmia, U wave change, atrial flutter/fibrillation, peripheral ischemia, and thrombophlebitis/phlebitis. Rarely, cases of sustained supraventricular and ventricular arrhythmias, cardiac arrest leading to death, and myocardial infarction have been reported during postmarketing experience.
Similarly, results of a review of the cardiovascular effects of the drug class 5-hydroxytryptamine 3 receptor antagonists in the literature reported that electrocardiographic (ECG) changes were so small to be considered clinically insignificant. ECG changes were most noticeable between 1 to 2 hours after a dose of dolasetron and returned to baseline within 24 hours. To date, no serious cardiac side effects (including torsades de pointes) triggered by ECG interval changes have been connected with the use of 5-HT 3 receptor antagonists.
Dermatologic side effects have rarely included rash and increased sweating.
Ocular side effects have included blurred vision (6.3%), visual disturbance (3.2%), and photophobia (1.6%).
Hematologic side effects have included hematuria, epistaxis, prolonged prothrombin time, increased PTT, anemia, purpura/hematoma, and thrombocytopenia.
Hypersensitivity side effects have rarely included anaphylactic reaction, facial edema, and urticaria.
Metabolic side effects have rarely included increased alkaline phosphatase.
Musculoskeletal side effects have rarely included myalgia and arthralgia.
Psychiatric side effects have rarely included nervousness (3.2%). Agitation, sleep disorder, and depersonalization have been reported infrequently. Confusion, anxiety, and abnormal dreaming have been reported rarely.
Respiratory side effects have rarely included dyspnea and bronchospasm.
Genitourinary side effects have rarely included dysuria and polyuria.
Renal side effects including acute renal failure have been reported.
Other side effects including taste perversion have been reported infrequently. Tinnitus has been reported rarely.
More about Anzemet (dolasetron)
Compare with other treatments for:
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.